GMEP方案治疗难治性或复发性非霍奇金淋巴瘤的近期疗效报告

目的：评价GMEP方案治疗难治性或复发性非霍奇金淋巴瘤（non-Hodgkin’s lymphoma．NHL）的近期疗效及不良反应。方法：30例难治性或复发性NHL患者接受GMEP方案化疗：健择（GEM）1000mg／m^2d1,8．静滴．米托蒽醌（MIT）6—8mg／m^2d1,静滴。足叶乙甙（VP-16）60mg／m^2d1-5，静滴，强的松（PDN）60mg／m^2口服。d1—5，每3～4周重复。疗程不少于3个周期。结果：全组30例患者均按计划完成化疗。随诊率93．3％。中位生存期11．3个月，1年生存率为43．3％．2年生存率为30．8％。治疗后总缓解率为80％（24／30）．其中CR6例（20％），PR18例（60％）。10例具有B类症状的患者中，6例症状消失。2例明显改善。2例无改善。化疗最常见的不良反应为骨髓抑制、胃肠道反应和肝功能损害。结论：GMEP方案治疗难治性或复发性NHL．近期疗效较好。毒性反应轻。患者可以耐受。

GMEP REGIMEN IN THE TREATMENT OF RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA:A REPROT OF SHORT TERM EFFICACY

Objective:To evaluate the therapeutic effect and toxicity of GMEP regimen in relapsed or refractory non- Hodgkin's lymphoma(NHL).Method:A tottal of 30 relapsed or refraetory NHL patients received a course of GMEP regimen, Gemcitahine(GEM)1000mg/m~2 iv d_(1-5).MIT VD-16 PDV Repeat every 3-4weeks.Results:All the patients completed chemotherapy.The follow-up rate was 93.3% with a median survival duration of 11.3 months.The 1-year and 2-year survival rates were 43.3%,30.8%,respectively.Total response rate was 80%,with CR for6(20%),PR for 18(60%),and 6 in 10 patients were alleviated of type B symptoms.The main adverse effects were myelotoxieity, nausea/vomiting.Conclusion: GMEP regimen can be safely preformed for the patients with relapsed or refractory non-Hodgkin's lymphoma and the short- term response in comparable to the results of others.